MYMD NASDAQ
Baltimore, MD 21205
US
MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical development stage, focused on devising diverse therapeutic strategies that target the underlying origins of various illnesses. One of its key initiatives is the development of MYMD-1, a drug platform centered on a small molecule presently undergoing clinical trials. This molecule works by regulating the immune system to suppress TNF-alpha, a major contributor to chronic inflammation, along with other pro-inflammatory cell-signaling proteins. MYMD-1 is being explored for its potential to delay aging, extend lifespan, manage autoimmune conditions, and treat depression linked to COVID-19. Furthermore, the company is advancing Supera-CBD, a synthetic version of cannabidiol, which aims to address chronic pain, addiction, and epilepsy. MyMD Pharmaceuticals was established in 2014 and its corporate headquarters are situated in Baltimore, Maryland.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Friscia Stephen | 0 | — | 2024-06-13 | |
| Glass Mitchell | 0 | — | 2024-04-08 | |
| Rivard Paul | P-Purchase | 150,000 | $1.11 | 2023-08-24 |
| Rivard Paul | P-Purchase | 25,000 | $1.12 | 2023-08-17 |
| Chapman Christopher | A-Award | 300,000 | $1.66 | 2023-06-07 |